Philip Morris International has entered the U.S. market with smoke-free products, including Iqos Iluma, which could be a game changer once approved. The stock is a buy and hold opportunity, with smoke-free products accounting for 41% of the company’s revenue. The company is awaiting FDA approval for Iqos Iluma, which could lead to a significant growth opportunity in the U.S. market. Analysts estimate the business will grow earnings at an annualized rate of 11% over the long term. Investors might look back at 2026 as a pivotal year for the company.

Read more at Nasdaq, Inc.: Philip Morris International: Why 2026 Could Be the Tipping Point for Its Smoke-Free Dominance